PF-Atlas › Clinical Trials › NCT03625466
A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
LUM/IVA · Phase 2
Registry ID
NCT03625466
Phase
Phase 2
Status
Completed
Drug / intervention
LUM/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2018-08-10
About this trial
LUM/IVA is evaluated in NCT03625466, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03625466 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.